Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2024
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms HOPE-3
- Sponsors Capricor Therapeutics
- 24 Apr 2024 According to a Capricor Therapeutics media release, company announced an update from the Company's recent Type-B Chemistry, Manufacturing and Controls meeting with the U.S. Food and Drug Administration on next steps for the Biologics License Application submission with its lead asset CAP-1002 in treating Duchenne muscular dystrophy.
- 29 Feb 2024 According to a Capricor Therapeutics media release, the company expect to complete enrollment in the second quarter of 2024.
- 27 Feb 2024 According to a Capricor Therapeutics media release, this trial fully enrolled in Cohort A and top-line data expected in the fourth quarter of 2024.